340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

HRSA Withdraws 340B Mega-Reg, Will Issue Guidance Instead

Publication expected early next year 

November 13, 2014—The Health Resources and Services Administration is withdrawing its planned comprehensive 340B program regulation tomorrow morning and instead will issue guidance early next year revising policies for key program elements. … [Read more...]

MedPAC Briefed About 340B Paper Requested by Lawmakers

Commission will not vote on findings or make recommendations to Congress 

November 10, 2014—Medicare Payments Advisory Commission staff members briefed the panel last week about a commission paper on the 340B program requested by congressional Medicare oversight committees.   … [Read more...]

In Elections’ Wake, New Senate Leadership and a New GAO Study on 340B

Report is due to be issued in mid-2015 

November 5, 2014—U.S. Senate committees with responsibility for the 340B drug discount program will have new leaders starting early next year following the GOP's strong showing in yesterday's midterm elections.      … [Read more...]

OIG Assessing Risk of Medicaid MCO Rebates on 340B-Purchased Drugs

Also, study about 340B and Medicare Part B is still on track 

November 4, 2014—The Department of Health and Human Services Office of Inspector General is assessing the risk of manufacturer discounts and rebates both being paid on 340B-purchased drugs dispensed to Medicaid managed care beneficiaries, the OIG said in its fiscal year 2015 work plan.   … [Read more...]

Orphan Drugs to Be Almost 20% of Global Drug Sales by 2020

Industry's "rush into orphan indications" shows no signs of stopping 

October 31, 2014—Orphan drugs will account for almost 20 percent of total worldwide drug sales (excluding generics) by the end of the decade, with year-to-year sales growth more than double that of the overall prescription drug market, the market intelligence firm EvaluatePharma says in a new report. … [Read more...]

Hospitals Protest Genentech’s Deeming Cancer Drugs as Specialty Meds

State Medicaid chiefs, meanwhile, say Sovaldi might need federal price controls 

October 30, 2014—Hospital groups are protesting Genentech's decision to make them buy three very expensive and much-used cancer drugs exclusively through specialty distributors, saying the change is raising their costs and potentially compromising patient care without enhancing patient safety or supply-chain security. … [Read more...]

Infographic: 340B DSH Hospitals Have Huge Low-Income Patient Loads and Uncompensated Care Costs

 

Pass it along. … [Read more...]

« Previous Page
Next Page »

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health